Skip to main content

ANTI-SMAD7 (N-TERMINAL) ANTIBODY PRODUCED IN RABBIT AFFINITY ISOLATED ANTIBODY

Sigma Aldrich

Catalog No.
C15-1739-555
Manufacturer No.
SAB4200346-200UL
Manufacturer Name
Sigma-Aldrich
Quantity
1
Unit of Measure
EA
Price: $698.65
List Price: $1,074.84

General description SMAD7 (mothers against decapentaplegic homolog 7) is a Tbx1 (T-box 1) interacting gene and is encoded by the gene mapped to human chromosome 18q21.1.

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Adding to cart… The item has been added

General description

SMAD7 (mothers against decapentaplegic homolog 7) is a Tbx1 (T-box 1) interacting gene and is encoded by the gene mapped to human chromosome 18q21.1.

SMAD7 (mothers against decapentaplegic homolog 7), that binds the E3 ubiquitin ligase Smurf1/2. SMAD7 belongs to the family of inhibitory Smads (I-Smads).

Immunogen

peptide corresponding to the N-terminal region of human SMAD7, conjugated to KLH. The corresponding sequence is identical in monkey and differs by 2 amino acids in mouse and rat.

Application

Anti-SMAD7 (N-terminal) antibody produced in rabbit has been used in immunoblotting and immunofluorescence.

Biochem/physiol Actions

SMAD7 (mothers against decapentaplegic homolog 7) is a modulator of TGFβ (transforming growth factor β) signaling in immune cells which are associated with ulcerative colitis and inflammatory bowel syndrome. It plays a major role in the etiology of CRC (colorectal cancer). In addition, it also acts as a mediator of the negative feedback loop for both the TGFβ and BMP (bone morphogenetic proteins) signaling pathways. It is essential for the remodelling of pharyngeal artery and the enlargement of great vessel. In mouse, homozygous removal of Smad7 causes primarily fourth-related arch artery defects. Silencing of Smad7 in RCD (refractory coeliac disease) biopsy samples can decrease the expression of interleukin-6 and tumour necrosis factor-α. Polymorphism of this gene is associated with colorectal cancer. SMAD7 is an inhibitor of the TGFβ (transforming growth factor beta) /BMP (bone morphogenetic proteins) pathway.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

UPC:
51202416
Condition:
New
Availability:
3-5 Days
Weight:
1.00 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
SAB4200346-200UL
Product Size:
200/µL

Cenmed Satisfaction Guarantee
Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

Testimonial
"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR

Testimonial
"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER

Testimonial
"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN

Testimonial
"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.